Regulated information

Vetoquinol acquires Equity Stake in Plant Advanced Technologies PAT

Lure and Nancy - November 13, 2017: Vetoquinol, a leading player in the animal health sector, and Plant Advanced Technologies PAT, a plant biotechnology company, announce Vetoquinol’s acquisition of an equity stake in Plant Advanced Technologies PAT. The transaction was carried out via a €500,000 reserved capital increase at a price of €25 per share resulting in the veterinary group holding an equity stake of just over 2% in PAT. 

Q3 2017 sales of €88.3 million, up 5.2% at constant exchange rates

For the third quarter of 2017, the Vetoquinol Group posted sales of €88.3 million, up 5.2% from Q3 2016 at constant exchange rates.

Reference products up 6.1% like-for-like in H1 net income group share up 6.5% to €14.4 million

At its meeting on July 26, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first half of 2017.

Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2017 (french)

Communiqué de mise à disposition  du rapport financier semestriel relatif à l’exercice 2017 

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2016 (french version)

The registration document of Vetoquinol relative to fiscal year 2016, including the annual financial report relative to fiscal year 2016, was filed with the Autorité des marchés financiers ("the AMF") on April 26, 2017.

Q1 2017 sales stable at €86.1 million

Consolidated sales for Q1 2017 amounted to €86.1 million, up 0.4% as reported from the same period last year. Sales were boosted by a 1.8% positive currency impact mainly related to non-European currencies. Q1 sales fell 1.4% like-for-like. 

All key financial indicators up in 2016

At its meeting on March 22, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2016 financial statements. 

2016 sales: €350.3 million 4.3% like-for-like growth

The Vetoquinol Group posted sales of €350.3 million for 2016, representing like-for-like growth of 4.3%. After a negative currency impact of 2.0% mainly linked to the British pound, Canadian dollar and Indian rupee, reported growth amounted to 2.3%.

Q3 2011 Sales

Vétoquinol achieved Q3 2011 sales of €68.4 million, in line with the previous year.

Jacques du Puy appointed Vétoquinol Managing Director

Lure (France), October 12, 2011 – The Vétoquinol Group announces the appointment
of Jacques du Puy as Managing Director.

Forcyl®: european launch of new drug

Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection.

Vétoquinol continues to develop its product ranges and enters the brazilian market

Lure (France), August 30, 2011 – The Vetoquinol Board Meeting of August 29, 2011 reviewed the Group’s business and approved the financial statements for the first half 2011.

International expansion and new product launches

Lure (France), July 19, 2011 – Vétoquinol Group sales rose to €139.7 million in the first six months of 2011.

European launch of new Nsaid Cimalgex®

Lure (France), June 14, 2011 – Vetoquinol announces the European launch of CIMALGEX®, a new treatment for pain and inflammation in dogs.

VÉTOQUINOL enters the brazilian Market

Lure (France), June 7, 2011 – Vetoquinol announces the acquisition of 100% of the equity of Farmagricola SA in Brazil.

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2010 (french version)

The registration document of Vétoquinol relative to fiscal year 2010, including the annual financial report relative to fiscal year 2010, was registered with the Autorité des marchés financiers (“the AMF”) on April 18th, 2011.

Net Sales rise 3% to €66.4 Million in the first Quarter of 2011

The Vétoquinol group reported a 3.0% rise in first quarter 2011 net sales to €66.4 million, compared to the same period last year.

2010 annual earnings

Lure (France), April 4, 2011 – Vétoquinol’s Board of Directors, meeting on March 18, 2011, has reviewed the Group’s business and approved its 2010 financial statements.

Redemption of tranche B bonds

Lure, 28 February 2011 – Vétoquinol S.A. has announced the redemption of the 58,927 tranche B bonds reaching maturity on 27 February 2011, by their conversion into common shares.

2010 Revenues grow 11.8%, driven by organic growth

The Vétoquinol Group reports sustained sales growth driven by its “hybrid” business model, supported by a sound level of organic growth.